Fourth-Quarter and Full-Year 2025 Results Supplemental Earnings Results Presentation February 12, 2026 Safe Harbor Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding management's goals, plans, and expectations, our future financial performance, our future financial projections, our growth strategy, and other matters. Forward looking statements generally can be i ...

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-. ...

Equillium (NasdaqCM:EQ) Conference February 12, 2026 03:30 PM ET Company ParticipantsBruce Steel - CEO and Co-FounderStephen Connelly - Chief Scientific Officer and Co-FounderModeratorThis Fireside Chat, the team from Equillium, Bruce and Stephen are on with us. Lots to cover over the next 28 minutes, so if you have any questions, I think all of you know the housekeeping rules. Just send your questions over to us, or put them into the Q&A box in Zoom, and we'll direct them to Bruce and Steve. Team, I think ...

PresentationI would now like to turn the conference over to Natasha Wagner. You may begin.Hello, and thank you for standing by. At this time, I would like to welcome everyone to the CareDx Investor Webinar Call. [Operator Instructions]Natasha Moshirian Wagner Hello, and thank you for joining us. I'm Natasha Wagner, VP of Corporate Communications at CareDx. Welcome to our investor webcast focused on AlloHeme, advancing AI-enabled relapse monitoring in AML and MDS post-cell therapy, positioning CareDx to lead ...

[https://www.pumabiotechnology.com].## ContactsAlan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500 [info@pumabiotechnology.com] [ir@pumabiotechnology.com]David Schull, Russo Partners, +1 212 845 4200 [david.schull@russopartnersllc.com]Industry:- [Oncology]- [Science]- [Pharmaceutical]- [Health]- [Biotechnology]- [Practice Management]- [Clinical Trials]- [FDA]- [Research]### Puma Biotechnology, Inc.NASDAQ:PBYI---Release SummaryPuma Biotechnology will issue its fourth quarter and ...

Pharmaceutical Inc.## 21%[more press release views with Request a Demo]## Also from this source### BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility[BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced offering of $850 million of 5.500%...]### BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility[BioMar ...

REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced a proposed underwritten public offering of its common stock (the “Offering”). In addition, Coherus intends to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares offered in the Offering, at the public offering price per share less underwriting discounts and commissions. All of the shares in the Of ...

REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended December 31, 2025. Congenital Hyperinsulinism (HI) In December 2025, Rezolute reported topline results from sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety ...

MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Charles (Chip) R. Romp to its Board of Directors. Mr. Romp brings over 25 years of experience in the pharmaceutical industry to Celcuity, including leadership of sales teams and commercial organizations in the oncology setting. “Chip brings a wealth of oncology-related commercial expertise to our Board, ...

Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO) and certain officers. The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 26-cv-00803, is on b ...